Abstract:
Compounds of formula I, uses as crosslinking agents or curing agents thereof, and resins obtained by using the compounds as crosslinking agents.
Abstract:
The invention relates to a method for producing a compound of fonnula (I), comprising the reaction, in the presence of a catalytic system comprising a single rare earth oxide or a mixture of rare earth oxides, of an alkyl carbonate or an alkylene carbonate with a polyol of fonnula (II), wherein p is a whole number between 2 and 10.
Abstract:
Disclosed are a catalyst for synthesizing glycerol carbonate from glycerol and a method for producing the catalyst. The method includes adding an aqueous NaOH solution, an aqueous KOH solution, or a mixture of an aqueous NH4(OH) solution and an aqueous NaOH solution to an aqueous solution of a mixture of zinc nitrate and aluminum nitrate, aging the mixture, filtering and washing the aged mixture to obtain a solid, and calcining the solid under an oxygen, nitrogen or helium atmosphere. The use of the catalyst enables the synthesis of glycerol carbonate from glycerol and urea with high conversion rate, selectivity and yield. Further disclosed is a method for synthesizing glycerol carbonate from glycerol using the catalyst.
Abstract:
The present invention relates to a synthesis process of polyol carbonate, such as glycerol carbonate, from polyols such as glycerol, propylene glycol or ethylene glycol and urea conducted in using a solvent selective for polyols (glycerol) carbonates. Said process comprises reacting polyol with urea in the presence of a catalyst, extracting produced NH3 and in addition in the presence in the course of at least one step of the process of a selective solvent for polyol carbonate allowing to extract it from the reaction medium.
Abstract:
A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administrationA 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.
Abstract:
The invention pertains to a process for preparing compounds of formula (I-A) or (I-B) here below: by reaction of perfluoroallylfluorosulfate (FAFS) of formula (II): with at least one hypofluorite of formula (II-A) or (II-B): wherein: RF in formulae (I-A) and (II-A) is a monovalent fluorocarbon C1-C20 group, optionally comprising oxygen catenary atoms, optionally comprising functional groups comprising heteroatoms (e.g. —SO2F groups); R′F in formulae (I-B) and (II-B) is a divalent fluorocarbon C1-C6 group, preferably a group of formula wherein X1 and X2, equal to or different from each other, are independently a fluorine atom or a C1-C3 fluorocarbon group. The FAFS-hypofluorite adducts of formulae (I-A) and (I-B) can be produced with high selectivity so as to access useful intermediates which can further be reacted taking advantage of the un-modified fluorosulfate group chemistry.
Abstract:
Compositions of matter comprising 5-phenylalkoxypsoralen compounds and their method of synthesis and use. The compounds are useable to treat diseases or disorders in human or veterinary patients, including autoimmune diseases such as multiple sclerosis. The compounds inhibit potassium channels, including the Kv1.3 channel and at least some of the therapeutic effects of such compounds may be due at least in part to potassium channel inhibition.
Abstract:
This invention relates to unsubstituted and polymeric leuco colorants for use as consumer product additives to indicate a product function by color change, to make attractive or distinctive visual effects, or to provide latent or delayed color generation. The colorants may be present in a stable, colorless state and may be transformed to an intense colored state upon exposure to certain physical or chemical changes. Alternatively, the colorants may be transformed from one color to another color upon exposure to certain physical or chemical changes. The colored form of the unsubstituted or polymeric leuco colorant may be transient, since the colorant can revert back to its colorless form or its original color after the physical or chemical activation has been removed or changed. Polymeric leuco colorants are typically comprised of at least two components: at least one leuco chromophore component and at least one polymeric component.
Abstract:
An alkylene carbonate is produced by the reaction of an alkylene oxide with carbon dioxide in the presence of a phosphonium compound as catalyst in a process in which (a) the alkylene oxide, carbon dioxide and the phosphonium catalyst are continuously introduced into a reaction zone from which a product stream containing alkylene carbonate and catalyst is withdrawn, (b) alkylene carbonate and a mixture of alkylene carbonate and phosphonium catalyst are separated from the product stream, (c) the alkylene carbonate, separated in step (b), is recovered as product, and (d) the mixture of alkylene carbonate and phosphonium catalyst is continuously recycled to the reaction zone. The alkylene carbonate thus produced is suitably reacted with an alkanol to produce an alkane diol and a dialkyl carbonate.
Abstract:
The invention relates to a method for producing glycerol carbonate methacrylate in the presence of metal-chelate catalysts of the metal ion-1,3-diketonate type.